On October 27, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, reported that two abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, to be held November 8-12, 2022 onsite in Boston, MA and online (Press release, Kineta, OCT 27, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-present-pre-clinical-data-on-vista-and-cd27-programs-at-sitc-2022-annual-meeting [SID1234622498]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thierry Guillaudeux, Ph.D., Kineta’s Chief Scientific Officer, will highlight developmental progress of two of the Company’s novel immuno-oncology antibody therapeutics. The poster presentations will provide an overview of KVA12123 (formerly referred to as KVA12.1), Kineta’s IND-ready VISTA blocking immunotherapy for the treatment of cancer patients with advanced solid tumors that is scheduled to initiate a Phase 1 clinical trial in the fourth quarter of 2022, and the anti-CD27 agonist antibody lead candidate in development for the treatment of advanced solid tumors.